Please join us on April 20th, 2023 at 12:00 PM ET for LifeSci’s virtual webinar series “Lunch with LifeSci” featuring VectivBio, featuring Luca Santarelli, CEO of VectivBio, a promising late-stage clinical biotech company focusing on Short Bowel Syndrome with Intestinal Failure (SBS-IF). SBS-IF is a devasting orphan disease affecting 17,000 people in the US and Europe. These patients have extreme difficulty absorbing nutrients where they are supposed to – in their intestines. VectivBio’s lead product candidate, apraglutide, is a regenerative medicine that improves intestinal absorptive capacity and improves GI function.

Our “Lunch with LifeSci” series highlights promising healthcare investment opportunities by simplifying the complex and making them accessible and digestible to generalist investors who appreciate the alpha it can generate in their investment portfolios.

VectivBio is one such promising company… apraglutide, their once weekly injectable drug, represents a blockbuster opportunity in SBS-IF as validated by the competitor’s $800M in sales, once daily, drug. VectivBio’s once weekly injection has a good chance of being better than the once daily.  There are two upcoming catalysts which could generate significant investor interest. First, interim results from their Phase 2 GvHD trial expected in the second quarter of 2023. Second, their Phase 3 data in their all-important Adult SBS-IF trial expected by year end 2023. With cash runway into 2025 and the support of prominent shareholders such as OrbiMed, Forbion, Versant, Citadel, Eventide, Cormorant, and Blackstone, we are excited to introduce you to the management of VectivBio.